As of September 30, 2025, cash and cash equivalents totaled $42.7 million. The Company believes that it has a cash runway into 2027.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Ten new option listings on November 5th
- Optimistic Buy Rating for Unicycive Therapeutics Driven by Promising Clinical Progress and Financial Stability
- Unicycive Therapeutics to present new OLC data at ASN Kidney Week 2025
- Unicycive Therapeutics price target raised to $22 from $9 at H.C. Wainwright
- Unicycive Therapeutics Updates FDA Application for OLC